FGF TECHNOLOGY REPRESENTS MAJOR BREAKTHROUGH IN METABOLIC AND CANCER DISEASES
Boston, MA – May 6, 2025 – Anzor Pharmaceuticals is honored to announce its selection as a presenting company at the 2025 BioLabs-NYU Investor & Innovator Exchange, taking place on May 6, 2025, in New York City. This high-profile event, now in its second year, is co-hosted by BioLabs@NYULangone, NYU Langone Health, and NYU Technology Opportunities & Ventures, and brings together leading life sciences startups, investors, and industry strategics from across the nation.
The Investor & Innovator Exchange is recognized as a premier platform for emerging biotech companies to showcase their innovations, connect with top-tier investors, and compete for opportunities such as fully funded lab space at BioLabs@NYULangone’s state-of-the-art Manhattan facility. Anzor Pharmaceuticals’ selection reflects the company’s commitment to advancing breakthrough therapies and its growing reputation within the life sciences ecosystem.
“We are thrilled to be chosen to present at this year’s BioLabs-NYU Investor & Innovator Exchange,” said Chris Adams, CEO, of Anzor Pharmaceuticals. “This event is an exceptional opportunity to share our latest research on chronic kidney disease and drug pipeline with an audience of visionary investors and industry leaders, and to further our mission of delivering transformative therapies to patients in need.”
The conference will feature pitch sessions, expert panels, and networking opportunities designed to foster collaboration and accelerate innovation in healthcare and biotechnology.
For more information about Anzor Pharmaceuticals, please visit www.anzorpharma.com.
About Anzor Pharmaceuticals
Anzor Pharmaceuticals is at the forefront of targeted fibroblast growth factor (FGF) therapies for cancer and metabolic disorders. The company’s technology is based on proprietary FGF peptides and conjugates, with applications in obesity, chronic kidney disease, and skeletal disorders. Extensive research has demonstrated that FGF receptors are involved in several key pathways of disease.
